CLINICAL_TRIALS
trial_result
· 2026-03-24
Clinical Trial Update: BCMA/CD3 Bispecific Antibody Treatment for Newly Diagnosed Amyloidosis [Phase 2]
Summary
Phase 2 trial update on a BCMA/CD3 bispecific antibody for newly diagnosed systemic AL amyloidosis; the study is currently recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Systemic Light Chain Amyloidosis | Phase 2 | Status: RECRUITING